BioSpace News Archive

Glucotrack, Inc., a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it will participate in the Sidoti Small Cap Investor Conference.

GENFIT announced the achievement of a historic corporate milestone: the U.S. Food and Drug Administration accelerated approval of Iqirvo1 2 80 mg tablets – as unveiled today by Ipsen – as a first-in-class treatment for PBC in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

Tharimmune, Inc. reports positive results from its Phase 1 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene that easily adheres inside of the mouth on the cheek and biodegrades within minutes.

Crinetics Pharmaceuticals, Inc. announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Mirum Pharmaceuticals, Inc. announced that on June 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 56,600 shares of common stock and 28,300 restricted stock units to 14 new employees under Mirum’s 2020 Inducement Plan.

Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company developing N-myristoyltransferase (NMT) inhibitors to treat hematologic cancers and solid tumors.

A new study guided by a renowned surgeon at City of Hope®, one of the largest cancer research and treatment organizations in the United States, demonstrates that robotic liver surgery can be a safe, outpatient procedure.

Hudson Therapeutics announced that Shaperon, an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding with Dong-A ST for the development of nanobody-based new drugs.

Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced that it has published its first Sustainability Report, highlighting the Company’s sustainability activities, performance, and results from the last three years.